When used in everyday practice, sodium-glucose cotransporter 2 (SGLT2) inhibitors provide rapid and sustained benefits to patients with a recent heart failure (HF) hospitalization, a nationwide ...

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2 ...

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients ...

The two questions addressed in this “pragmatic” trial — whether adjunctive SGLT2 inhibitors are beneficial after TAVI and whether SGLT2 inhibitors are safe in older patients — were ...

Compared with placebo, SGLT2 inhibitors reduced heart failure hospitalizations among patients with history of myocardial infarction. Sodium-glucose co-transporter 2 (SGLT2) inhibitors may ...

With the expiration of Boehringer Ingelheim’s patent on Empagliflozin, several Indian pharmaceutical companies are set to introduce significantly lower-priced generic versions. This move aims to ...

SGLT2 inhibitors were linked to better outcomes relative to GLP-1s. In a real-world study, SGLT2 inhibitors and GLP-1 agents were more effective than dipeptidyl peptidase-4 inhibitors and ...

Most patients who qualify for an SGLT2 inhibitor are not prescribed one. Prescription rates for those with a class 1a recommendation are about 11% for those with diabetes and 3% for those without ...

In a real-world study of patients aged 60 years or older with diabetes, SGLT2 inhibitor users experienced a significantly slower decline in estimated glomerular filtration rate compared with DPP4 ...

SGLT2 inhibitors, such as empagliflozin (Jardiance) and dapagliflozin (Farxiga), reduced the risk of sight-threatening retinopathy by 21-39% versus GLP-1 receptor agonists, DPP-4 inhibitors ...

United Laboratories International has been granted a patent for a [1,2,4]triazolo[1,5-a]pyridine compound as a JAK inhibitor for treating diseases related to JAK1 or/and TYK2. The compound, ...